Cargando…

Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications

BACKGROUND: Cytogenetic abnormalities are considered initiating events in the pathogenesis of multiple myeloma (MM) and are assumed to be of clinical significance. METHODS: Fluorescence in situ hybridization (FISH) was used to analyze chromosomal architecture in 101 patients with MM. We evaluated ov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, He, Zhou, Shuping, Lin, Hongdou, Guo, Wenjian, Lin, Ying, Yao, Ronxin, He, Licai, Yu, Kang, Li, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941557/ https://www.ncbi.nlm.nih.gov/pubmed/35342415 http://dx.doi.org/10.1155/2022/4112016

Ejemplares similares

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma
por: Dementyeva, Elena, et al.
Publicado: (2013)

Observational Evidence for Desert Amplification Using Multiple Satellite Datasets
por: Wei, Nan, et al.
Publicado: (2017)

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2011)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Allosteric Inhibition of c-Abl to Induce Unfolded Protein Response and Cell Death in Multiple Myeloma
por: Kosako, Hideki, et al.
Publicado: (2022)

Recent Progress of Exosomes in Multiple Myeloma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Strategies
por: Wang, Xi, et al.
Publicado: (2021)

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
por: Hanamura, Ichiro
Publicado: (2021)

Anaplastic multiple myeloma with amplification of the IGH-CCND1 gene fusion
por: Alencar, Rafael Nobrega, et al.
Publicado: (2023)

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications
por: Vakana, Eliza, et al.
Publicado: (2011)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
por: Shin, Junghoon, et al.
Publicado: (2017)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

Expression of Neuron-Specific Enolase in Multiple Myeloma and Implications for Clinical Diagnosis and Treatment
por: Yang, Haiping, et al.
Publicado: (2014)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies
por: Allegra, Alessandro, et al.
Publicado: (2021)

Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors
por: Nakajima, Kosei, et al.
Publicado: (2020)

The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
por: Cencini, Emanuele, et al.
Publicado: (2023)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia
por: Koka, Rima, et al.
Publicado: (2017)

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma
por: Thomas, Alexandra L., et al.
Publicado: (2015)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

Evolving therapeutic role of bisphosphonates in multiple myeloma
por: Ural, A U, et al.
Publicado: (2005)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
por: Weiser Drozdkova, Denisa, et al.
Publicado: (2021)

Therapeutics to harness the immune microenvironment in multiple myeloma
por: Ignatz-Hoover, James J., et al.
Publicado: (2022)

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
por: Zarone, Mayra Rachele, et al.
Publicado: (2017)

Maxillary Swelling as the First Evidence of Multiple Myeloma
por: Kasamatsu, Atsushi, et al.
Publicado: (2015)

Panobinostat for the treatment of multiple myeloma: the evidence to date
por: Bailey, Hanna, et al.
Publicado: (2015)

Evidence-based supportive care in multiple myeloma
por: Qureshi, Anum, et al.
Publicado: (2020)

Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
por: Yu, Zhen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ek4rk867t0i3cqcovnhuvpk714